SEC Filing Summary: GSK Plc (Form 6-K)
Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of July 2020. The report serves as a notification to the market in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R regarding the Company's total voting rights and capital structure as of June 30, 2020.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a capital structure notification and does not contain financial performance data.
Material Changes
The filing details the Company's issued share capital as of June 30, 2020:
- Total issued shares: 5,384,977,518 Ordinary Shares of 25 pence each.
- Treasury shares held: 367,705,950 Ordinary Shares.
- Total voting rights: 5,017,271,568.
The filing does not explicitly state material changes compared to a prior comparable period, but provides the definitive denominator for shareholder notification calculations under FCA rules.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of share capital and voting rights.
Key Facts for Investor Verification
- Verify the total number of voting rights (5,017,271,568) against the Company's latest annual report to confirm the denominator for ownership threshold calculations.
- Confirm the number of shares held in Treasury (367,705,950) to understand the difference between issued capital and voting capital.
- Note that this filing does not contain operational or financial performance metrics for the period.